Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Advances in prostate cancer - a decade in review

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.01.14
Views: 5181
Rating:

Dr Karim Fizazi, Dr Cora Sternberg, Dr John Fitzpatrick, Dr Heather Payne, Dr Peter Nelson

This expert panel discussion took place at ASCO GU 2014. Dr Karim Fizazi (Institut Gustave Roussy, Paris, France) chairs the discussion between Dr Peter Nelson (Fred Hutchinson Cancer Research Center, Seattle, USA), Dr Cora Sternberg (San Camillo-Forlanini Hospital, Rome, Italy), Dr John Fitzpatrick (Irish Cancer Society, Dublin, Ireland) and Dr Heather Payne (University College Hospital, London, United Kingdom).

The panel discuss the changing landscape of prostate cancer over the last decade and how this has impacted on treatment practices and outcomes for patients.

They cover:

Abstract LBA1: Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of the phase III PREVAIL study.

1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer  (CRPC) and bone metastases from the phase III ALSYMPCA study.

Results from a phase III, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).

And further discuss:

- The potential future of the evolving treatment options in CRPC

- Clinical strategies to overcome androgen resistance

- Treatment options are available for patients with CRPC

- The correct sequence for the use of newly available drugs for the management of CRPC

- Patient sub-groups that can optimally benefit from new treatment approaches

 


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Core Surgical Training


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation